TipRanks
Advertisement
Advertisement

JP:4599 Stock Latest News

StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease
Company AnnouncementsStemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease
4d ago
4599
StemRIM Plans Zero-Cost Stock Options to Align Talent With Long-Term Growth
PremiumCompany Announcements
StemRIM Plans Zero-Cost Stock Options to Align Talent With Long-Term Growth
16d ago
4599
StemRIM Strengthens Governance Ahead of Growth Drive
PremiumCompany Announcements
StemRIM Strengthens Governance Ahead of Growth Drive
16d ago
4599
StemRIM Secures South Korean Patent for Redasemtide in Cartilage Disorders
PremiumCompany Announcements
StemRIM Secures South Korean Patent for Redasemtide in Cartilage Disorders
16d ago
4599
StemRIM Grants New Stock Options to Directors as Regenerative Medicine Pipeline Advances
PremiumCompany Announcements
StemRIM Grants New Stock Options to Directors as Regenerative Medicine Pipeline Advances
1M ago
4599
StemRIM Sets Terms for New Employee Stock Option Issuance
PremiumCompany AnnouncementsStemRIM Sets Terms for New Employee Stock Option Issuance
1M ago
4599
StemRIM Deepens Losses but Secures Funding for Regenerative Medicine Push
Premium
Company Announcements
StemRIM Deepens Losses but Secures Funding for Regenerative Medicine Push
1M ago
4599
StemRIM Issues New Director Stock Options With Limited Dilution
Premium
Company Announcements
StemRIM Issues New Director Stock Options With Limited Dilution
1M ago
4599
StemRIM Issues New Employee Stock Options With Limited Dilution Impact
PremiumCompany Announcements
StemRIM Issues New Employee Stock Options With Limited Dilution Impact
1M ago
4599
StemRIM Secures South Korean Patent for Gene Therapy Targeting Rare Skin Disease
PremiumCompany Announcements
StemRIM Secures South Korean Patent for Gene Therapy Targeting Rare Skin Disease
2M ago
4599
StemRIM Wins Mexican Patent for Redasemtide Cartilage Therapy
PremiumCompany Announcements
StemRIM Wins Mexican Patent for Redasemtide Cartilage Therapy
3M ago
4599
StemRIM Secures Canadian Patent for Regenerative Heart Drug Redasemtide
PremiumCompany Announcements
StemRIM Secures Canadian Patent for Regenerative Heart Drug Redasemtide
3M ago
4599
PremiumCompany AnnouncementsStemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder
3M ago
4599
StemRIM to Record AMED Subsidy as Non-Operating Income for Gene Therapy Project
Premium
Company Announcements
StemRIM to Record AMED Subsidy as Non-Operating Income for Gene Therapy Project
4M ago
4599
StemRIM Wins Australian Patent for Redasemtide Cartilage Disorder Therapy
Premium
Company Announcements
StemRIM Wins Australian Patent for Redasemtide Cartilage Disorder Therapy
4M ago
4599
StemRIM Wins Russian Patent to Expand Redasemtide Use in Fatty Liver and NASH
PremiumCompany Announcements
StemRIM Wins Russian Patent to Expand Redasemtide Use in Fatty Liver and NASH
4M ago
4599
StemRIM posts continued loss but secures R&D runway through 2028
PremiumCompany Announcements
StemRIM posts continued loss but secures R&D runway through 2028
4M ago
4599
StemRIM Plans Tax-Efficient Capital Reduction Ahead of July Extraordinary Meeting
PremiumCompany Announcements
StemRIM Plans Tax-Efficient Capital Reduction Ahead of July Extraordinary Meeting
5M ago
4599
StemRIM Highlights Shionogi’s Timelines for Regenerative Drug Redasemtide in DEB and Stroke
PremiumCompany Announcements
StemRIM Highlights Shionogi’s Timelines for Regenerative Drug Redasemtide in DEB and Stroke
5M ago
4599
StemRIM Completes Enrollment in Early-Stage Redasemtide Trial for Ischemic Cardiomyopathy
PremiumCompany AnnouncementsStemRIM Completes Enrollment in Early-Stage Redasemtide Trial for Ischemic Cardiomyopathy
6M ago
4599
StemRIM Unveils Midterm FY2026 Results and R&D Progress in Regenerative Medicine
Premium
Company Announcements
StemRIM Unveils Midterm FY2026 Results and R&D Progress in Regenerative Medicine
7M ago
4599
StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline
Premium
Company Announcements
StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline
7M ago
4599

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >